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Background: Mechanistic within-host models relating blood anti-malarial drug concentrations with the
parasite-time profile help in assessing dosing schedules and partner drugs for new anti-malarial treatments. A
comprehensive simulation study to assess the utility of a stage-specific pharmacokinetic-pharmacodynamic (PK-PD)
model for predicting within-host parasite response was performed.
Methods: Three anti-malarial combination therapies were selected: artesunate-mefloquine, dihydroartemisinin-
piperaquine, and artemether-lumefantrine. The PK-PD model included parameters to represent the
concentration-time profiles of both drugs, the initial parasite burden and distribution across the parasite life cycle,
and the parasite multiplication factor due to asexual reproduction. The model also included the maximal killing rate
of each drug, and the blood drug concentration associated with half of that killing effect (in vivo EC50), derived
from the in vitro IC50, the extent of binding to 0.5% Albumax present in the in vitro testing media, and the drugs
plasma protein binding and whole blood to plasma partitioning ratio. All stochastic simulations were performed
using a Latin-Hypercube-Sampling approach.
Results: The simulations demonstrated that the proportion of patients cured was highly sensitive to the in vivo
EC50 and the maximal killing rate of the partner drug co-administered with the artemisinin derivative. The in vivo
EC50 values that corresponded to on average 95% of patients cured were much higher than the adjusted values
derived from the in vitro IC50. The proportion clinically cured was not strongly influenced by changes in the
parameters defining the age distribution of the initial parasite burden (mean age of 4 to 16 hours) and the parasite
multiplication factor every life cycle (ranging from 8 to 12 fold/cycle). The median parasite clearance times,
however, lengthened as the standard deviation of the initial parasite burden increased (i.e. the infection became
more asynchronous).
Conclusions: This simulation study demonstrates that the PD effect predicted from in vitro growth inhibition assays
does not accord well with the PD effect of the anti-malarials observed within the patient. This simulation-based
PK-PD modelling approach should not be considered as a replacement to conducting clinical trials but instead as a
decision tool to improve the design of a clinical trial during drug development.
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Despite significant progress in control of malaria over
the last decade, it remains a major global health prob-
lem. Almost 40% of the world’s population live in mal-
aria endemic areas, with each year about a quarter of a
billion people experiencing clinical malaria and an esti-
mated 655,000 malaria-related deaths [1]. With no vaccine
currently available, malaria control relies on preventative
measures (i.e. insecticidal bed nets and indoor residual
spraying) and effective treatment with artemisinin-based
combination therapy (ACT). ACT involves treatment
with two or more anti-malarials; a fast acting but short
lived artemisinin derivative and a less effective, but of
longer duration, partner drug. ACT is recommended
by WHO as the first-line treatment of uncomplicated
falciparum malaria [2], but recent reports from west-
ern Cambodia raise concerns that Plasmodium falciparum
has developed reduced susceptibility to oral artesunate
[3,4]. In the context of emerging resistance to artesunate
(the most widely used artemisinin derivative), it is critical
that new anti-malarial treatments are developed and
assessed.
Mechanistic within-host pharmacokinetic-pharmaco-
dynamic (PK-PD) models that relate blood anti-malarial
drug concentrations to the parasite-time profile have
potential to aid anti-malarial drug development. Simu-
lated parasite-time profiles for hypothetical patients
can be generated from the mechanistic PK-PD model
and incorporate between-patient variability in the drug
concentration profiles. Comparisons of parasitological
outcomes (e.g. distribution of parasite clearance times
and proportion of patients cured) derived from these
hypothetical individuals can then be used as a decision
tool for assessing dosing schemes and potential partner
drugs for new anti-malarial drugs. This simulation-
based approach has been adopted previously using a
within-host continuous-time PK-PD model for com-
paring dosing schemes of mefloquine [5,6], artesunate
[7], chloroquine [8], and the ACT, mefloquine and
artesunate [9]. More recently a parasite stage-specific
discrete-time within-host PK-PD model has been
developed, and a stochastic simulation-based ap-
proach implemented to compare dosing schemes for
artesunate [10].
In this paper, the above stage-specific model was
extended to account for the action of two or more anti-
malarial treatments, and the anti-malarial pharmacody-
namic parameters were determined by extrapolating from
in vitro data. Using a Latin-Hypercube-Sampling approach
[11], the sensitivity of the PK-PD model to particular para-
meters was assessed, by comparing, across different sets of
parameter values, the parasitological outcomes derived
from simulated parasite-time profiles of hypothetical
patients.Methods
Within-host pharmacokinetic-pharmacodynamic model
The within-host PK-PD model is based on that described
in Saralamba et al. [10], which is a discrete-time model
that incorporates the age distribution of the parasite
population within the malaria patient. This model deter-
mines how the distribution of the parasite age changes
post treatment as a consequence of the concentration of
the anti-malarial drug. The general form of the discrete-
time model (see Saralamba et al. [10] supplemental in-
formation for more detail) and PK-PD parameter values
used to simulate individual parasitaemia-time profiles in
the presence of anti-malarial combination therapies is
described below.
Prior to drug administration, the initial parasite load
of each patient (P0i) is distributed among the 48 hourly
age intervals of the P. falciparum life cycle according to
a Gaussian distribution with a mean age of μ hours and
a standard deviation of σ hours (see Additional file 1).
The expected number of parasites in patient i (Ni a; tð Þ)
aged ‘a’ hours (where 1 ≤ a ≤ 48) at hourly time point t after
drug administration, is expressed by the following differ-
ence equations,
Ni a; tð Þ ¼ Ni a 1; t  1ð Þeki a1;t1ð Þ for 1 < a ≤48 ð1Þ
and
Ni 1; tð Þ ¼ PMF  Ni 48; t  1ð Þeki 48;t1ð Þ for a ¼ 1:
ð2Þ
In (1) and (2), ki a; tð Þ is the kill rate constant for the
combination therapy of the parasites aged a hours at
hourly time point t, and in (2), PMF is the parasite
multiplication factor that represents the number of
merozoites released per schizont at the end of the 48
hour life cycle that successfully reinvade red blood cells.
The kill rate constant for a particular combination
therapy was calculated as follows:
ki a; tð Þ ¼ kdrug1;i a; tð Þ þ kdrug2;i a; tð Þ ð3Þ
where drugj , for j = 1, 2, denotes one of the drugs comp-
rising a combination therapy. The kill rate constant in (3)
assumes that the effects of drug1 and drug2 on the parasite
population in vivo are independent of one another.
The relationship between the kill rate constant for
each drug and the drug concentration is given by:
ki a; tð Þ ¼ kmax að Þ  ci tð Þγ= ci tð Þγ þ ECγ50
   ð4Þ
where ci tð Þ is the plasma drug concentration at time t
for patient i, γ is the slope of the concentration-effect re-
lationship, EC50 is the blood drug concentration in vivo
that gives 50% parasite killing and kmax is the maximal
killing rate of each drug (which was assumed to be
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known to have an effect).
The drug concentration-time curve ci tð Þ for each drug
assumes the form of a structural PK model, for example
a one- or two- compartment PK model with first-order
absorption and elimination from the central body
compartment.Simulation study
The model was implemented using R [12]. Parasite
counts at several different time points and in the pres-
ence of anti-malarial combination therapies were simu-
lated from this discrete-time model for hypothetical
malaria patients. The summary measures that were
derived from each simulated parasite count-time curve
were: (i) the hypothetical patient was clinically cured
(defined as the parasite count falling below 2.5 × 108
parasites (i.e. 50 parasites per μL) and not reappearing
above 2.5 × 108 parasites by day 63 of follow-up); and (ii)
the parasite clearance time (PCT) (hours), defined as the
time for the circulating parasite count (parasites aged
approximately 1 to 26 hours) to decrease below 2.5 × 108
parasites. Circulating parasite counts were calculated
from the total parasite counts following Saralamba et al.
[10], where sequestration was estimated to start at a
parasite age of 11 hours and the number of parasites older than
11 hours circulating in the blood was assumed to decrease
exponentially.
The anti-malarial combination therapies selected for
this simulation study were three artemisinin-based com-
bination therapies: artesunate-mefloquine, dihydroartemi-
sinin-piperaquine, and artemether-lumefantrine. Studies
of in vitro interactions between the pharmacodynamic
effects of the drugs have shown no interaction between
dihydroartemisinin and piperaquine [13], and a small
amount of synergy between artesunate and mefloquine
[14], and between artemether and lumefantrine [15].
Thus, the assumption of independent pharmacodynamic
effects of each drug in the combination therapies selected
for this simulation study seems reasonable, especially con-
sidering the short amount of time (approximately six
hours for dihydroartemisinin and twelve hours for arte-
mether) that the drug concentrations of the artemisinin
derivatives are present in the blood.Table 1 Dosing regimen for each artemisinin-based
combination therapy (ACT)
ACT Dosing regimen (WHO)
ARS-MQ ARS 4.0 mg/kg and MQ 8.3 mg/kg at 0, 24, 48 h
ART-LF ART 80.0 mg/kg and LF 480.0 mg/kg at 0, 8, 24, 36, 48, 60 h
DHA-PQ DHA 4.0 mg/kg and PQ 18.0 mg/kg at 0, 24, 48 h
ARS – artesunate, ART – artemether, DHA – dihydroartemisinin,
LF – lumefantrine, MQ – mefloquine, PQ – piperaquine.Pharmacokinetic-pharmacodynamic parameters
In order to assess the utility of the PK-PD model for de-
termining patient outcomes (described above) the sensi-
tivity of the model to parameter values was explored.
This was implemented using Latin-Hypercube-Sampling
(LHS). LHS is a method which is used to randomly sam-
ple over large parameter spaces in an evenly distributed
manner [11].Before carrying out the LHS sampling, pharmacoki-
netic profiles of each anti-malarial drug for the three
artemisinin-based combination therapies were simulated
for 100 hypothetical patients. The dosing regimen used
was the regimen recommended by the WHO ([2]; see
Table 1) and the PK profiles were simulated using par-
ameter values and between-subject variability obtained
from the literature (see Table 2 and Additional file 2)
[16-19].
The PD parameters were varied across the LHS experi-
ment to capture both biological and empirical uncer-
tainty. The definition of each PD parameter and the
statistical distribution selected for each PD parameter
are given in Table 3 and Table 4, respectively. For the
parameters that are drug independent, the distributions
for the parameters which determine how the parasites
are distributed across the 48 hours of the parasite life
cycle (μ and σ) were sourced from PK-PD modelling of
uncomplicated falciparum malaria patients [10] and the
distribution for the parasite multiplication factor (PMF)
was obtained from modelling of data collected from
syphilis patients treated with an induced malaria infec-
tion [20,21].
The maximal killing rate (kmax) of the drug was
assumed to follow a triangular distribution. The middle
values were taken from published clinical data [3,22,23].
Piperaquine was the only drug with no clinical studies of
it administered as a monotherapy and the mode was set
to a value equal to that derived from in vitro experi-
ments [24]. The minimum and maximum values of the
triangular distribution for each anti-malarial correspond
to a 50-fold decrease and 50-fold increase in the number
of parasites killed every 48 hours. Artesunate, dihydroar-
temisnin and artemether were assumed to kill parasites
aged 6 to 44 hours; mefloquine 18 to 40 hours; pipera-
quine (assumed similar to chloroquine) 12 to 36 hours;
and lumefantrine (assumed similar to mefloquine) 18 to
40 hours [25].
The slope of the concentration-effect curve (i.e. in vivo γ)
was assumed to have the same statistical distribution
(i.e. Log-normal) and parameter values (mean and standard
deviation on loge scale) as the in vitro γ which was derived
from modelling of in vitro concentration-effect curves mea-
sured from a large number of parasite isolates.
Table 2 Population pharmacokinetic parameter values
(BSV%)† for each drug
Drug
PKa parameter ARS/DHAb ART LF MQ PQc
ka (/h) 19.7
d 0.37 0.17 7d 0.717
(26.5%) (63%) (52%) (26%) (168%)
CL/F (L/h) 24.2e 180 7.04 0.8e 66
(22.4%) (50%) (16%) (33%) (42%)
V/F (L) 0.83f 217 - 10.2f -
(50%) (30–50%) (51%)
Vc/F (L) - - 103 - 8660
(30–50%) (101%)
Q/F (L/h) - - 4.08 - 131
(30–50%) (85%)
Vp/F (L) - - 272 - 24000
(30–50%) (50%)
ARS – artesunate, ART – artemether, DHA – dihydroartemisinin,
LF – lumefantrine, MQ – mefloquine, PQ – piperaquine.
†Parameter values were taken from the literature: dihydroartemisinin [16],
artemether [17], lumefantrine[17], mefloquine[18], piperaquine [19]. Between-
subject variability (BSV%) presented as standard deviation multiplied by 100
(lognormal error model).
aka – absorption rate constant; CL/F – clearance; V/F – volume of distribution;
Vc – volume of central compartment; Q – inter-compartmental clearance; and
Vp –volume of peripheral compartment.
bDihydroartemisinin profiles were simulated for artesunate, since
dihydroartemisinin is the primary active metabolite of artesunate and
artesunate is considered the pro-drug.
cPK parameters are for a 48kg individual.
d/day.
eL/kg/day.
fL/kg.
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is unknown, therefore, the conservative continuous-
uniform distribution was chosen with the minimum value
set to the adjusted in vitro IC50 and the maximum value
equal to half of the maximum concentration of the popu-
lation mean PK profile.
Five thousand parameter sets were selected from the
above statistical distributions using LHS. For each par-
ameter set, simulated parasite count versus time profiles
for the 100 hypothetical patients (with the PK profilesTable 3 Parameter definitions for the within-host
pharmacokinetic-pharmacodynamic model
Parameter Description
μIPL Mean of the age distribution of the initial parasite burden
σIPL Standard deviation of the age distribution of the initial
parasite burden
PMF Parasite multiplication factor (/48 h cycle)
kmax Maximal killing rate of the drug / h
γ Slope of in vivo concentration-effect curve
EC50 In vivo concentration when killing rate is 50% of the
maximumdetermined above) were derived for each artemisinin-
based combination therapy. The initial parasite burden
for each of the 100 hypothetical patients was randomly
selected from a log-normal distribution with a geometric
mean of 1.14 × 1011 (i.e. parasitaemia of 22746 parasites
per μL) and a standard deviation on the log-scale of
1.13. The initial parasite burdens for the 100 patients
did not vary with LHS parameter set or with the artemi-
sinin combination therapy used in the simulation.
Determination of the in vitro IC50 and slope (γ) of
concentration-effect relationship
Estimates of the in vitro IC50 (not corrected for binding)
and γ for artesunate, dihydroartemisinin, mefloquine,
piperaquine, and lumefantrine (refer to Table 5), were
determined from statistical modelling of individual iso-
late effect versus drug concentration curves. The fresh
P. falciparum parasite isolates were obtained from blood
samples of 487 patients attending outpatient clinics in
Papua, Indonesia between 2004 and 2010 [26]. The
in vitro drug susceptibility was determined using the
World Health Organization guidelines for schizont mat-
uration tests. The in vitro data for artemether were mea-
sured at the Swiss Tropical and Public Health Institute
(Switzerland; Basel) against asynchronous intraerythro-
cytic forms of the P. falciparum strain NF54 (obtained
from MR4) using the [3H]-hypoxanthine incorporation
assay [27].
The in vitro free drug IC50 was calculated from the
measured in vitro IC50 (uncorrected for binding) by
multiplying by the unbound fraction in the in vitro test-
ing media. This value was then converted to an adjusted
in vitro IC50 in whole blood (to represent concentra-
tions comparable to an in vivo situation) by first dividing
by the free fraction in plasma and then multiplying by
the whole blood to plasma ratio (see Table 5).
Estimates of drug binding to the in vitro testing media
(i.e. 0.5% Albumax in RPMI) and human plasma were
determined using ultracentrifugation. Briefly, blank Albu-
max media and plasma were each spiked with compound
and divided into six aliquots; three aliquots were subjected
to ultracentrifugation (Beckman Optima XL-100K Ultra-
centrifuge, Rotor type 42.2 Ti; 223,000 x g) for 4.2 hours
at 37°C to pellet the proteins whereas the remaining three
aliquots served as controls and were incubated at 37°C for
the same time period but without centrifugation. Controls
were also stored at −20°C to confirm sample stability over
the centrifugation period. Aliquots of the supernatants
from the ultracentrifuged samples were first diluted 1:1 in
acetonitrile, assayed by LC-MS and the responses com-
pared to a calibration curve prepared in 50% aqueous
acetonitrile to determine the unbound (i.e. free) concen-
tration. Control concentrations in each matrix were deter-
mined using LC-MS by first precipitating the proteins
Table 4 Statistical distributions selected for each pharmacodynamic parameter
Parameter Drug Distributionb Additional details
μIPL
a DU(4, 16)
σIPL
a DU(2, 8)
PMF a TRI(8, 12, 10)
kmax ARS/DHA TRI(0.26, 0.47, 0.37)
c PRR = 105.28; KZ = 38
ART TRI(0.12, 0.33, 0.22)c PRR = 102.9; KZ = 38
LF TRI(0.18, 0.54, 0.36)c PRR = 103; KZ = 22
MQ TRI(0.11, 0.46, 0.28)c PRR = 102.25; KZ = 22
PQ TRI(0.33, 0.65, 0.49)c PRR = 104.6; KZ = 24
γ ARS/DHA lnN(1.31, 0.65)
ART lnN(1.53, 0.31)
LF lnN (0.81, 0.58)
MQ lnN (0.97, 0.54)
PQ lnN (1.35, 0.66)
EC50 (ng/mL) ARS/DHA U(1.44, 532.05) a ¼ IC50 (adjusted)(ng/mL)b,d; b ¼ 0.5×Cmax (ng/mL)b,d
ART U(4.38, 46.20)
LF U(1.75, 2331.60)
MQ U(20.48, 1087.22)
PQ U(11.56, 94.19)
ARS – artesunate, ART – artemether, DHA – dihydroartemisinin, LF – lumefantrine, MQ – mefloquine, PQ – piperaquine.
aDrug independent parameters.
bDU – Discrete-uniform (DU (a, b); a < b; a and b positive integers); TRI – Triangular (TRI (a, b, c); a < c < b; a, b and c real numbers); lnN – Log-normal
(lnN (μ ln, σ ln); μ ln and σ ln positive real numbers); and U – Continuous-uniform: (U (a, b); a < b; a and b real numbers).
cThe mode of the triangular distribution for kmax (c) was calculated from the following expression: kmax ¼ 1=KZð Þ  ln PRRð Þ½  þ 1=48ð Þ  ln PMFð Þ½ , where PRR is
the parasite reduction ratio for the drug in the corresponding row; KZ is the length of the killing zone in hours for each drug in the corresponding row; PMF in
this expression equals 10 parasites / 48 h. The lower /upper limit of the triangular distribution for kmax (a/b) is calculated by evaluating the latter expression kmax
at a PRR decreased/increased by 50-fold (KZ remains unchanged).
d IC50 (adjusted) = IC50 × (100 – BM / 100) × (100 / 100 - HPPB) × HWB;
BM – binding media; HPPB – human plasma protein binding; HWB – human whole blood to plasma ratio. IC50 (adjusted) values for each drug are given in
Table 5 and Cmax is the peak plasma concentration of a drug after administration.
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paring the responses to a calibration curve from a blank
matrix prepared using the same protein precipitation pro-
cedure. The free fraction in each matrix was then deter-
mined from the ratio of the average unbound (e.g. free)Table 5 Parameter values derived from in vitro experiments
Parameter
IC50 measured concentration(nM)†
Molecular weight (g/mol)
IC50 concentration(ng/mL)
Binding to media of in vitro experiment (0.5% Albumax) (% bound)
Human plasma protein binding (% bound)
Human whole blood to plasma ratio
Scalar (adjusted)
IC50 (adjusted) concentration (ng/mL)†
γ (Slope of concentration-effect curve)
SD of γ on log-scale
ARS – artesunate, ART – artemether, DHA – dihydroartemisinin, MQ – mefloquine, P
†Geometric mean.concentration to the average total concentration in each
matrix.
The whole blood to plasma partitioning ratio (B/P)
was determined by spiking aliquots of whole blood or
plasma maintained at 37°C with compound, incubatingARS/DHA ART LF MQ PQ
1.39 - 13.42 9.34 17.67
384.4 - 528.9 378.3 535.5
0.53 2.64 7.1 3.53 9.46
82.8 82.8 99.6 85 98.1
93 91.7 98.7 95.6 98.6
1.1 0.8 0.8 1.7 0.9
2.7 1.66 0.25 5.8 1.22
1.44 4.38 1.75 20.48 11.56
3.72 4.61 2.24 2.63 3.48
0.65 0.31 0.58 0.54 0.66
Q – piperaquine, LF – lumefantrine.
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to obtain the plasma fraction. Both the plasma fraction
of whole blood and the plasma control were assayed for
compound by LC-MS as described above. The blood to
plasma ratio was calculated from the ratio of the con-
centration in the plasma control (used as a surrogate for
the total whole blood concentration since whole blood
assays were not available for each compound) to that in
the plasma fraction of whole blood. The two-minute
time point was used to avoid confounding issues due to
potential blood instability; rapid equilibration between
plasma and erythrocytes was assumed.
Results
Sensitivity of pharmacokinetic-pharmacodynamic (PK-PD)
model to parameter values
Examined first was the model’s sensitivity to the three
parameters that describe the function of the parasite: theProportions of cured
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Figure 1 Tornado plots of partial rank correlation coefficients, indicat
and standard deviation of the age distribution of the initial parasite b
the variability in the proportion cured (left) and parasite clearance timparasite multiplication factor (PMF), the mean for the
age distribution of the initial parasite burden (μ), and
the standard deviation of the age distribution of parasites
within each host (σ). For each drug combination therapy
and model output (proportion clinically cured and
PCT), Figure 1 shows tornado plots of the partial rank
correlation coefficients (PRCCs). The magnitude of the
PRCC indicates the importance of the uncertainty in es-
timating the parameters governing the age distribution
of the initial parasite burden (μ and σ) and the PMF in
contributing to the variability in the proportion clinically
cured and the PCTs. A negative PRCC indicates that the
model output tends to decrease as the parameter
increases and a positive PRCC indicates that the model
output tends to increase as the parameter increases.
Figure 1 (left panel) shows that the proportion clinic-
ally cured (for ease of exposition referred to subse-
quently as proportion cured) after treatment withPCTs
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http://www.malariajournal.com/content/11/1/303artemether-lumefantrine was sensitive to changes in the
standard deviation of the age distribution of the initial
parasite burden, and that it tended to decrease as the
standard deviation of the age distribution (i.e.σ)
increases (i.e. as the infection becomes more asyn-
chronous). The proportion cured after treatment with
artemisinin-lumefantrine was not strongly influenced
by changes in the mean of the age distribution of the
initial parasite burden (i.e. μ) and the PMF. The pro-
portion cured for the remaining artemisinin combin-
ation therapies was not very sensitive to changes in the
parameters defining the age distribution of the initial
parasite burden (i.e. μ and σ) and the PMF.
The PCTs for all three artemisinin combination therap-
ies were sensitive to changes in the mean and standard
deviation of the age distribution of the initial parasite
burden (see Figure 1, right panel). The PRCCs plotted in
the right panel of Figure 1 show that the PCTs for all
three artemisinin combination therapies tended to
lengthen as the standard deviation of the age distribution
increased (or the infection became more asynchronous)Pr
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the proportion cured simulated for 5000 parameter values of EC50 (or kmax
parameters were varied.and tended to shorten as the mean of the age distribution
increased.
Tornado plots of the PRCCs between the model out-
puts and the drug dependent parameters (EC50, kmax
and γ) for each artemisinin combination therapy are also
provided in Additional file 3.
Artesunate-mefloquine
Figure 2 depicts the distribution of the proportion cured
for the combination therapy artesunate-mefloquine
across deciles of the 5,000 parameter values for EC50
(drug concentration in vivo that corresponds to 50%
parasite killing) and kmax (maximum killing rate con-
stant) for both artesunate and mefloquine. The propor-
tion of patients cured from the simulated parasite-time
profiles was highly correlated with the in vivo EC50 and
kmax for mefloquine, whereas the influence of the artesu-
nate parameter values was marginal. Lower killing rates
of mefloquine predicted a reduction in the percentage of
patients being cured, the median value ranging from
10% to 95% for kmax<0.187 (i.e. Parasite Reduction RatioPr
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http://www.malariajournal.com/content/11/1/303(PRR) <101.33) up to kmax>0.301 (i.e. PRR>10
2.42). Only
when the EC50 concentrations of mefloquine were be-
tween 447 to 554 ng/ml, much higher than the adjusted
in vitro IC50 value (21 ng/ml), was the predicted me-
dian proportion cured similar to that observed in clin-
ical studies [3,28,29]. With EC50 values between 661–
874 ng/ml approximately 75% (on average) of the hypo-
thetical patients were predicted to be cured. Figure 3
illustrates that PCTs are not vulnerable to the EC50
and kmax values of mefloquine and artesunate. Further-
more the values of the slope of either the artesunate or
mefloquine concentration-effect curves had no associ-
ation with any of the model outputs (see Additional
files 4A-B).Dihydroartemisinin-piperaquine
Similarly for the combination of dihydroartemisinin-
piperaquine, the proportion of patients cured correlated
closely with the in vivo EC50 for the long acting partner
drug, piperaquine (Figure 4), but was not influenced by
values of EC50 or kmax of dihydroartemisinin. However
in contrast to the mefloquine containing combination,50
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Figure 3 Distribution of parasite clearance times (hours) within the E
the anti-malarial combination therapy, artesunate (ARS) and mefloqu
right hand side) and bottom panels are for mefloquine (EC50 – left hand svalues of piperaquine kmax were only weakly associated
with the proportion cured. The median proportion cured
changed dramatically from 100% to 40% across the
deciles of EC50 values for piperaquine, with EC50 values
of 45 to 53 ng/ml corresponding to a median of 95%.
Figure 5 highlights that PCTs are not sensitive to kmax
values of dihydroartemisinin and piperaquine but are mar-
ginally sensitive to the EC50 values of piperaquine. The
values of the slope of either the dihydroartemisinin or
piperaquine concentration-effect curves had no associa-
tions with the model outputs (see Additional files 5A-B).Artemether-lumefantrine
For artemether-lumefantrine, the proportion of patients
cured was correlated with both parameters kmax and
EC50 of lumefantrine and marginally sensitive to both
parameter values of artemether (Figure 6). For lumefan-
trine, in vivo EC50 values of less than 235 ng/ml corre-
sponded to 100% cured and values of 1632 ng/ml and
above resulted in approximately 10-20% cured. For this
combination therapy, artemether is given at 0, 8, 24, 36,
48 and 60 hours, whereas for the above two combination50
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http://www.malariajournal.com/content/11/1/303therapies the artemisinin derivative is given only at 0, 24
and 48 hours. The additional doses of artemether may
explain why changes in the EC50 and kmax values of
artemether are associated with the proportion cured for
this artemisinin derivative. This was supported by the
results of a simulation run on the first 500 of the 5,000
LHS parameter sets with artemether given at 0, 24 and
48 hours and lumefantrine given at 0, 8, 24, 36, 48 and
60 hours (see Additional file 6). For PCTs, as with the
other partner drugs, no associations were observed for
the EC50 and kmax of lumefantrine (Figure 7). A slight
gradient was observed such that longer PCTs were
observed for those with higher artemether EC50 values.
The values of the slope of either the artemether or lume-
fantrine concentration-effect curves had no associations
with the model outputs (see Additional files 7A-B).
Comparing alternative dosing regimens
The utility of the mechanistic within host PK-PD model as
a decision tool for comparing dosing regimens was
investigated for different dosing schemes for each of the
partner drugs, mefloquine (WHO recommended dosing of
8.3 mg/kg at 0, 24 and 48 hours versus dosing of 15 mg/kgat 48 hours) and piperaquine (WHO recommended dosing
of 18 mg/kg at 0, 24 and 48 hours versus 36 mg/kg at 0, 24
and 48 hours), administered with the artemisinin deriva-
tives, artesunate and dihydroartemisinin respectively. Since
the proportion of patients cured was highly dependent on
the EC50 value of the partner drug (a parameter for which
we don’t know the value), different dosing schemes were
compared for the 25th, 50th and 75th percentile values of the
5000 parameter values selected using LHS. All other para-
meters were fixed at their mean/mode value given in
Table 4.
The proportion cured for 100 hypothetical patients with
varying PK profiles for the two dosing schemes of meflo-
quine was 100% when the EC50 value of mefloquine was
287 ng/ml, however, under-dosing patients with only
15 mg/kg of mefloquine resulted in only 50% of the patients
being cured if the EC50 is 554 ng/ml and 20% if the EC50
was 821 ng/ml. For the standard recommended mefloquine
dose of 8.3 mg/kg at 0, 24 and 48 hours, approximately
95% and 80% would be expected to be cured at the respect-
ive EC50 values of 554 and 821 ng/ml (Figure 8A).
Doubling the recommended WHO dose of piperaquine
given each day over 3 days results in a higher proportion
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http://www.malariajournal.com/content/11/1/303of patients cured at the EC50 values of 53 and 74 ng/ml
for piperaquine (Figure 8B).
Discussion
The parasitological outcomes simulated in this paper
were proportion of patients cured and parasite clearance
times, for three different artemisinin-based combination
therapies currently recommended by the WHO as the
first line treatment for uncomplicated falciparum mal-
aria. This simulation study was comprehensive, ran-
domly drawing from each distribution of the six key
pharmacodynamic parameters using Latin-Hypercube-
Sampling (LHS), and included between-patient variabil-
ity in the pharmacokinetic profiles of each anti-malarial
drug. The proportion of hypothetical patients cured was
observed to be highly correlated to the in vivo EC50 and
the killing rate (kmax) of the partner drug co-
administered with the artemisinin derivative. However,
in vivo EC50 values that corresponded to on average
95% of patients cured (a value observed in most clinical
efficacy studies of these regimens) were much higher
than the values we derived from in vitro data
(i.e. adjusted in vitro IC50), even though the differencein protein binding in vitro and in vivo were taken into
account in the model. In vitro experiments typically as-
sess the pharmacodynamic effect of an anti-malarial
drug by measuring inhibition of parasite growth in rising
concentration of free drug for the length of one parasite
life cycle (i.e. 48 hours). The duration of the in vitro
assay is usually 48 to 72 hours and although this permits
a reproducible estimate of parasite drug susceptibility, it
may be too short for this estimate to reflect accurately
clinical correlates. This may explain in part why in vitro
measures accord so poorly with the observed pharmaco-
dynamic effect in vivo.
There was evidence that the proportion cured decreased
if asynchronous infections were treated with artemether-
lumefantrine, but the synchronicity of the infection did
not strongly influence the proportion cured following
treatment with either artesunate-mefloquine or dihydroar-
temisinin-piperaquine. The PCT for all three artemisinin
combination therapies tended to lengthen as the infection
became more asynchronous and to shorten as the mean
age of the initial parasite burden increased. The finding
that asynchronous infections take longer to clear is plaus-
ible because it is more likely that there will be parasites
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Figure 6 Distribution of proportion cured within the EC50 and k1 deciles derived from the 5000 parameter sets for the anti-malarial
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http://www.malariajournal.com/content/11/1/303outside the killing zone (i.e. early rings and schizonts) dur-
ing the times when the patient is only exposed to the part-
ner drug (e.g. approximately 7 to 24 hours for mefloquine
or piperaquine). The distributions of PCTs in Additional
files 4B, Additional file 5B and Additional file 6B are bi-
modal because the hypothetical patients do not receive a
single dose of the artemisinin derivative but are given
multiple doses at 24 and 48 hrs (and also 8, 36 and 60
hours for artemether).
The proportion cured following treatment with
artesunate-mefloquine was highly correlated to the
in vivo EC50 value of mefloquine. This is not surprising
given the brief time the parasite is exposed to dihydroar-
temisinin concentrations (approximately 6 hours follow-
ing each dose of artesunate) compared to mefloquine
which remains in the body, on average, for 40 days. This
finding concurs with observations from deterministic
simulated individual patient parasite versus time profiles
using a continuous-time PK-PD model [9]. The associ-
ation between the proportion cured and the in vivo
EC50 values of piperaquine and lumefantrine was even
stronger than that observed for mefloquine. Both pipera-
quine and lumefantrine have an enormous volume ofdistribution and an elimination profile that comprises a
steep short distribution phase followed by a slow elimin-
ation phase from day 5–7 onwards[19,30]. However,
lumefantrine has a much lower volume of distribution
compared with piperaquine and this explains why higher
values of in vivo EC50 for lumefantrine are required be-
fore the simulated observations predict, on average, 10-
20% cured. PCTs did not increase when the maximal
killing rate (kmax) of artesunate/dihydroartemisinin
decreased, although this was observed for the ring stage
parasites in the discrete-time PK-PD model reported by
Saralamba et al. [10]. These conflicting findings are
likely to arise for a number of reasons. First, in this
paper it was assumed that the maximal killing rate of
the artemisinin derivatives was constant across the kill-
ing zone (i.e. the age range of parasites for which the
drug kills) since stage-specific killing rates for each anti-
malarial was not known. Second, kmax values for the ar-
temisinin derivatives were randomly selected from a
Parasite Reduction Ratio at 48 hours (PRR48) ranging
from 5× 104.28 to 5 × 106.28 with a mode value of 105.28
[3] parasites reduced every 48 hours. In the observations
by Saralamba et al. [10], the maximal killing rate of
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Figure 7 Distribution of parasite clearance times (hours) within the EC50 and k1 deciles derived from the 5000 parameter sets for the
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hand side) and bottom panels are for lumefantrine (EC50 – left hand side, kmax right hand side).
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http://www.malariajournal.com/content/11/1/303artesunate observed for the ring stages with delayed
PCTs was a mean of 62% /cycle corresponding to a
much lower PRR (~100.42) than our minimal value.
Third, in this study the partner drugs were administered
at the same times as the doses of the artemisinin deriva-
tives and therefore contributed to the parasite clearance
times whereas in Saralamba et al. only artesunate was
administered in the first 48 hours of treatment.
This simulation study has a number of strengths which
includes: the method of LHS for randomly selecting 5000
sets of the pharmacodynamic parameter values combined
with simulations of 100 pharmacokinetic profiles for each
anti-malarial to capture between-patient variability in drug
exposure. Moreover our comparison of alternative dosing
regimens highlight the utility of PK-PD models to com-
pare dosing schemes and have the capacity to examine the
association between a range of PK parameters (e.g. time
above therapeutic concentration, maximum concentration
or area under the concentration-time profile) and para-
sitological outcome. The limitations of this study were:
the within-host PK-PD model assumes that the back-
ground immunity of the hypothetical patients was low or
absent; no pharmacodynamic synergism between the two
anti-malarials of each combination therapy evaluated wasassumed; and the a priori assumption that the maximal
killing rate of the artemisinin derivatives and the partner
drugs remained constant across the different ages of the
parasite within the defined killing zone (e.g. 6 to 44 hours
for artesunate). Furthermore, the median PCTs were ap-
proximately 24 hours whereas in many clinical studies ap-
proximately 48 hours is often observed. This difference
may be due to one or a combination of factors including:
an assumption that there was no synergy between the
drugs; the maximal killing rate of the partner drug, pipera-
quine, was taken from an in vitro experiment and thus
may be higher than observed in vivo; and the number of
circulating parasites was calculated in time steps of one
hour post initial treatment for determining PCT whereas
in clinical efficacy studies this is often determined from
blood smears collected only every 24 hours.
In conclusion, this simulation study demonstrates the
utility of using mechanistic within-patient PK-PD models
for comparing parasitological outcomes of different dosing
schemes of anti-malarial treatments and different anti-
malarial combination therapies. The findings of this study
suggest that the parasitological outcomes be compared for
a number of scenarios of the pharmacodynamic parameter
values, especially the unknown in vivo EC50 value. These
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Figures 8 A-B Proportion of 100 hypothetical patients cured.
Panel A: EC50 values of mefloquine (287, 554 and 821 ng/ml) for
two different dosing schemes: 8.3 mg/kg at 0, 24 and 48 hours
(WHO standard; circles); and 15 mg/kg at 48 hours (alternative
scheme; crosses). Panel B: EC50 values of piperaquine (32, 53 and 74
ng/ml) for two different dosing schemes: 18 mg/kg at 0, 24 and 48
hours (WHO standard; circles); and 36 mg/kg at 0, 24 and 48 hours
(alternative scheme; crosses).
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http://www.malariajournal.com/content/11/1/303simulation studies should not be used as a replacement to
conducting the clinical efficacy trials but instead used to
assist in determining the best dosing schemes and poten-
tial partner drugs to be considered for new anti-malarial
treatments. This simulation-based approach has the po-
tential to reduce the number of clinical efficacy trials car-
ried out in the Phase II and Phase III stages of drug
development, which will reduce the cost of drug develop-
ment, speed up the process of drug registration, and could
help identify non-ethical trials of malaria patients.Additional files
Additional file 1: Age distribution of initial parasites burden.
Simulated number of parasites (/μL of blood) at each stage of the life
cycle – for a patient with a pre-treatment parasite burden of 1011
parasites, a mean parasite age of 8 hours and a standard deviation of 12
hours.
Additional file 2: Simulated pharmacokinetic profiles. Simulated
pharmacokinetic profiles of dihydroartemisinin, artemether, mefloquine,
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different colour) is the mean population PK profile.
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the variability in the proportion cured (left) and parasite clearance time
(PCT) (right) for each artemisinin combination therapy.
Additional file 4 A-B: Proportion cured and parasite clearance time
(PCT) for 100 hypothetical patients treated with artesunate (ARS)
and mefloquine (MQ) combination therapy. Proportion cured and PCT
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pharmacodynamic parameter values over 100 hypothetical patients with
varying ARS and MQ pharmacokinetic profiles. Panel A: Pharmacodynamic
parameters sampled using LHS versus proportion cured. Panel B:
Pharmacodynamic parameters sampled using LHS versus PCT.
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(PCT) for 100 hypothetical patients treated with dihydroartemisinin
(DHA) and piperaquine (PQ) combination therapy. Proportion cured
and PCT were calculated for each set of Latin hypercube sampled (LHS)
pharmacodynamic parameter values over 100 hypothetical patients with
varying DHA and PQ pharmacokinetic profiles. Panel A: Pharmacodynamic
parameters sampled using LHS versus proportion cured. Panel B:
Pharmacodynamic parameters sampled using LHS versus PCT.
Additional file 6: Distribution of proportion cured for a simplified
artemether-lumefantrine dosing regimen. Distribution of proportion
cured within the EC50 and kmax deciles derived from the first 500 of the
5000 parameter sets for the antimalarial combination therapy, artemether
(ART) and lumefantrine (LM) where artemether was given at 0, 24 and 48
hours and lumefantrine was given at 0, 8, 24, 36, 48 and 60 hours. Top
panels are for artemether (EC50 – left hand side, kmax right hand side)
and bottom panels are for lumefantrine (EC50 – left hand side, kmax right
hand side).
Additional file 7: A-B: Proportion cured and parasite clearance time
(PCT) for 100 hypothetical patients treated with artemether (ART)
and lumefantrine (LF) combination therapy. Proportion cured and
PCT were calculated for each set of Latin hypercube sampled (LHS)
pharmacodynamic parameter values over 100 hypothetical patients with
varying ART and lumefantrine LF pharmacokinetic profiles. Panel A:
Pharmacodynamic parameters sampled using LHS versus proportion
cured. Panel B: Pharmacodynamic parameters sampled using LHS versus
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